Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

Bayer bets on science in bid to prevent future Roundup lawsuits: legal experts

Stock MarketsJun 25, 2020 12:15AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters. FILE PHOTO: The historic headquarters of German pharmaceutical and chemical maker Bayer AG is pictured in Leverkusen

By Tina Bellon

(Reuters) - Seeking to forestall further claims, Bayer AG (DE:BAYGn) is taking a risky bet that an independent scientific review will ultimately show that its widely used weed killer Roundup does not cause cancer, legal experts said.

The company on Wednesday agreed to pay as much as $10.9 billion to settle about 75% of the 125,000 filed and unfiled claims by Roundup users who say the herbicide caused them to develop a form of blood cancer.

But Bayer (OTC:BAYRY) had to find a separate solution to mitigate the risk of future claims without pulling the product off the shelves. The company decided to make a calculated gamble on the scientific evidence which so far has overwhelmingly supported its claim that glyphosate, the active ingredient in Roundup, is safe for agricultural use.

Regulators worldwide, including the U.S. Environmental Protection Agency and the European Chemicals Agency, have determined glyphosate to be non-carcinogenic.

But the World Health Organization's cancer research arm determined the herbicide to be a "probable carcinogen" in 2015 and since 2018, three consecutive U.S. juries, who listened to scientific evidence from both sides during trial, found that Roundup causes cancer.

"Bayer is taking a huge risk by doing this and it's a bet that time can show that the science underlying the plaintiffs' claims is bad," said David Noll, a law professor at Rutgers University.

While many details of the proposal have yet to be released by Bayer and approved by a federal judge, the plan calls for an independent panel of scientific experts, who will likely be chosen and agreed upon by both sides.

The company will pay $1.25 billion to support the panel's research, an amount that does not include any payouts to settle future lawsuits.

The scientific review process is expected to take at least four years, and findings by the panel would be binding on Bayer and anyone who has used Roundup before Wednesday but not developed cancer.

If the panel finds glyphosate to be non-carcinogenic, those users could not sue.

If the panel determines glyphosate causes cancer, however, Bayer could face a flood of new lawsuits, with potential damages determined at a later stage. Bayer on Wednesday said the lead plaintiffs' lawyers have agreed to its plans, but Reuters was not immediately able to reach those attorneys for comment.

Lawyers for Roundup cancer claimants in the past have alleged that Bayer manipulated scientific studies and deceived the scientific community, claims Bayer denies.

Company executives on calls with reporters and analysts on Wednesday repeatedly said the science was in their favor.

"We are confident that the science panel will look at the scientific body of evidence and come to the conclusion that glyphosate is safe," said Bayer's global head of litigation, Bill Dodero.

Scientific panels have been set up in previous mass torts but generally not as part of a settlement process, legal experts said. Bayer's proposal was "creative but risky" and will likely face procedural challenges in court, said Adam Zimmerman, a professor at Loyola Law School.

The experts said many details, including how people who have not yet gotten sick could give up their rights to a future lawsuit under the proposal, remained unclear.

Bayer bets on science in bid to prevent future Roundup lawsuits: legal experts
 

Related Articles

Deutsche Post names Tobias Meyer CEO from 2023
Deutsche Post names Tobias Meyer CEO from 2023 By Reuters - Dec 08, 2021

BERLIN (Reuters) - Deutsche Post (OTC:DPSGY) said on Wednesday that Tobias Meyer will take over as new chief executive in May 2023 from long-serving boss Frank Appel, whose...

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Comments (1)
Matthew Carter
Matthew Carter Jun 25, 2020 12:44AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
who do they think they are kidding.??? safe my ******** sure they will buy their science support, like coke did with soda. after all, have enough money to throw at something you can change many peoples minds.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email